ReNeuron Group is pioneering the use of stem cells from human foetal tissue to develop treatments for neurological disorders including Huntington's disease and Parkinson’s. The outlook for the Guildford-based group hinges on its application with the US Food and Drug Administration to begin clinical trials of its stem cell therapy for strokes, for which there is currently no treatment. Its share price took a heavy knock this week when ReNeuron was asked to provide the FDA with more information, although the company is confident that approval will be granted. If so, it should begin human trials before the end of the year. California-based Stem Cells Inc won similar approval in 2006. ReNeuron shares, which closed at 40p yesterday, have surged threefold in the last two months. Should the stroke treatment succeed, rewards for shareholders would be enormous. Navid Malik, analyst at company broker Collins Stewart, set a price target of 126p for the stroke application alone. Investors with the stomach for risk may still want to consider buying the stock.